A SOX9 Duplication and Familial 46,XX Developmental Testicular Disorder
To the Editor: Female-to-male sex reversal in humans is rare, and when it is familial, it is extremely rare. We describe a family with a 46,XX testicular disorder of sex development in which three adult males (two brothers and a paternal uncle) were determined to be female according to karyotype (46,XX) and were negative for the SRY gene (Fig. 1) . The secondary sexual characteristics, behavior, growth and development, and skeletal development in these men were all normal male. Their general health and intelligence were normal. All three affected men were infertile with azoospermia. In two men, the testes were removed and prostheses were placed during their 20s because of testicular pain secondary to testosterone replacement. Histologic examination showed the presence of Leydig and Sertoli cells, severely diminished and atrophied seminiferous tubules, and no spermatogenesis. Male development is normally triggered by the transient expression of the Y chromosome gene SRY, which initiates a cascade of gene interactions orchestrated by SOX9, leading to the formation of testes from bipotential gonads. 1,2 The essential and nonredundant role of Sox9 in male development was initially detected in mice. Ectopic expression of Sox9 in the female gonad of XX mice caused complete female-to-male sex reversal, demonstrating that Sox9 is sufficient to trigger testis differentiation in the absence of Sry. 3, 4 T h e n e w e ng l a n d j o u r na l o f m e dic i n e n engl j med 364;1 nejm.org january 6, 2011
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We used single-nucleotide-polymorphism microarray analysis, in situ hybridization, and a long-range polymerase-chain-reaction assay to evaluate the family (Fig. 1) . The proband and his uncle had an approximately 178-kb duplication that was 600 kb upstream of SOX9. The duplication was arranged in tandem in wild-type orientation, and the joining points of the duplicated segments were uncorrupted. All affected family members carried the duplication, as did the proband's healthy, fertile 46,XY father. Neither his fertile daughter nor his fertile son carried the duplication. Of note, the 1.9-Mb region of chromosome 17 upstream of SOX9 contains no other genes and is evolutionarily highly conserved in mammals. SOX9 is a transcription factor essen- In Panel E, the amplicon is shown in blue. The wild-type region is 800 kb upstream of the SOX9 gene. The region duplicated is orientated by reference to the wild-type region. Specific PCR reactions used are shown: black bars confirm normal junctions between the duplicated segment and wild-type background, the blue bar indicates the breakpoint spanning the duplication-to-duplication, and the green bar encompasses two heterozygous SNPs (rs55812377 and rs12951210) to prove that both chromosome 17s were amplified.
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Copyright © 2011 Massachusetts Medical Society. All rights reserved. notices tial for both sex and skeletal development, and various perturbations to this 1.9-Mb region give rise to a range of phenotypes. 5 The pattern of autosomal dominant sex-limited inheritance in this family with transmission by a man with a normal male phenotype appears to be unique. Although SRY is normally needed for SOX9 activation and the male phenotype, in this family a small duplication alone seemed to be sufficient to override this fundamental genetic process. Only the sex-dependent expression of SOX9 was affected, presumably through specific enhanced promoter activity. This duplication, 600 kb distant from SOX9, exemplifies the complexities of transcription-factor control and illustrates the use of human studies in understanding developmental mechanisms. James J. Cox, Ph.D.
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corrections
In-Center Hemodialysis Six Times per Week versus Three Times per Week (December 9, 2010;363:2287-300). In Table 4 (page 2298), the 10th row under "Outcome" should have been "Episodes of hypotension," rather than "Episodes of hypertension." We regret the error. The article is correct at NEJM.org. Table 1 (page 1613), in the Self-Testing Group column, the parenthetical percentages given for "CHAD 2 score for patients who had AF without MHV" were incorrect for patients with scores of 1 to 5. Also, in the final paragraph of the Secondary End Points subsection of Results (page 1616), the second sentence should have ended ". . . with a mean interval between tests of 7.6±5.4 days . . .," rather than ". . 
